Price
No data yet.
Social Signal Score
50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1
Revenue
$17.89M+8.62%Jun 2021Mar 2026
Analyst Estimates
FY2025
$0.08
$0.08–$0.08
1 analysts
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew Mundy
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 826
- Beta
- 0.76
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.81
Financials
Revenue
$17.89M+8.6%Net Income
$-14.92MEBITDA
$-2.47MFree Cash Flow
$-3.19MEPS (diluted)
$-0.02Shares Outstanding (diluted)
674.37M+145.8%Operating Expenses
$8.24MR&DSG&A
Cash & Debt
$6.33MCash & investmentsTotal debt
Return of Capital
$0.00BuybacksDividends
Quote
Day Range
$0.02 – $0.02
52-Week Range
$0.00 – $0.08
Volume
$119.6K
Market Cap
$10.34M
50-Day Avg
$0.02
200-Day Avg
$0.03
Prev Close
$0.02
Open
$0.02
Valuation & Ratios
P/E Ratio
-0.42
EPS
$-0.12
P/B Ratio
-0.37
P/S Ratio
0.35
Debt/Equity
-1.73
Current Ratio
0.34
Dividend Yield
+0.0%
Gross Margin
+32.4%
Returns & Efficiency
Return on Equity
+89.5%
Return on Assets
-48.8%
FCF Yield
-49.5%
EV/EBITDA
-6.31
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $86.69M | $-72.50M | $-0.12 |
| 2024 | $103.56M | $-40.39M | $-0.13 |
| 2023 | $97.29M | $-22.75M | $-0.08 |
| 2022 | $87.69M | $-37.15M | $-0.15 |
| 2021 | $65.44M | $-19.00M | $-0.08 |
| 2020 | $52.39M | $-36.73M | $-0.18 |
| 2019 | $28.51M | $-53.23M | $-0.29 |
| 2018 | $8.06M | $-327.0K | $-0.00 |
| 2017 | $0.00 | $-10.14M | $-0.16 |
| 2016 | $0.00 | $-1.89M | $-0.03 |
Valuation
CNTMFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Aug 21Aug 21
Social Signal Score
50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
FLUENT Reports Second Quarter 2026 Results Q2 2026 Revenue brought in $17.1M Ended quarter with $4.5 million of cash and cash equivalents New Interim CEO appointed
View source ↗
Earnings
Wed, Aug 26(in 4 days)
1of 3 quarters beat consensus
Typical surprise -68.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 29$-0.04 vs $0.01miss
- Thu, Aug 22$0.00 vs $0.01miss
- Thu, May 30$-0.01 vs $-0.01beat
Estimates and results for CNTMF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.